Cara Therapeutics Inc (CARA)
0.6716
-0.04
(-5.02%)
USD |
NASDAQ |
Apr 24, 16:00
0.6777
+0.01
(+0.91%)
Pre-Market: 20:00
Cara Therapeutics Gross Profit Margin (Quarterly): 79.76% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 79.76% |
| September 30, 2023 | 67.98% |
| June 30, 2023 | 79.55% |
| March 31, 2023 | 57.99% |
| Date | Value |
|---|---|
| December 31, 2022 | 34.68% |
| September 30, 2022 | 71.75% |
| June 30, 2022 | |
| March 31, 2022 | 56.56% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
34.68%
Minimum
Dec 2022
79.76%
Maximum
Dec 2023
64.04%
Average
67.98%
Median
Sep 2023
Gross Profit Margin (Quarterly) Benchmarks
| Nektar Therapeutics | 69.51% |
| Stereotaxis Inc | 59.98% |
| Cerus Corp | 55.51% |
| Avid Bioservices Inc | -18.37% |
| Rigel Pharmaceuticals Inc | 89.41% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -108.3% |
| Return on Assets | -83.33% |
| Return on Invested Capital | -108.3% |
| Profit Margin (Quarterly) | -1.08K% |
| Operating Margin (Quarterly) | -1.09K% |
| Return on Net Operating Assets | -427.4% |